Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in mild to moderate COVID-19
NCT04429711Unknown
- Sponsor
- Sheba Medical Center
- Start
- May 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sheba Medical Center. Primary endpoints: Viral clearance at day 6, Viral shedding duration at 14 days and 1 more. Status: unknown.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04429711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429711.